Fig. 1
From: Chromogranin-A production and fragmentation in patients with Takayasu arteritis
Levels of CgA-derived polypeptides in patients with TA. a Plasma concentrations of total CgA, obtained summing the concentration of the full-length molecule with that of the various CgA fragments in patients with TA and HCs (see “Methods”). ***: significantly different from HCs, p ≤ 0.001. b Plasma concentrations of CgA439, CgA-FRs and VS-1 in patients with TA and HCs. *** and *: significantly different from HCs, p ≤ 0.001 and p ≤ 0.05 respectively. c Plasma concentrations of CgA439, CgA-FRs and VS-1 in TA patients with or without PPIs. ***: significantly different from patients without PPIs, p ≤ 0.001. d Ratios of CgA439, CgA-FRs and VS-1 to CgAtot in TA patients with or without PPIs. e-f Plasma concentrations of CgA439, CgA-FRs and VS-1 in normotensive versus hypertensive patients either in the whole group of TA patients (panel e) and in those on PPIs (panel f). *: significantly different from normotensive patients. AH arterial hypertension, CgA 439 full-length chromogranin-A (residues 1–439), CgA-FRs, fragments of CgA spanning from the N-terminus to the central region but lacking the C-terminal region, CgA tot total CgA, HC healthy controls, PPI proton-pump inhibitors, TA Takayasu arteritis, VS-1 vasostatin-1